StockNews.AI
STXS
StockNews.AI
23 days

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

1. STXS launched MAGiC Sweep, a robotically-navigated EP mapping catheter. 2. Successful initial procedures were conducted at Deborah Heart and Lung Center. 3. MAGiC Sweep offers high-density mapping for diagnosing arrhythmias. 4. Catheter received FDA clearance; European submission is underway. 5. Experts commend the catheter's performance and ease of use.

6m saved
Insight
Article

FAQ

Why Bullish?

The successful launch and positive feedback on MAGiC Sweep could drive demand and increase revenues, similar to historical product launches that significantly impacted stock prices positively.

How important is it?

The announcement provides significant product advancement and market validation, likely leading to stock price appreciation, backed by strong early reception.

Why Short Term?

The commercial launch and FDA approval will likely lead to immediate sales growth, as seen with prior successful product entries in med-tech.

Related Companies

ISRGMDTABMD
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world’s first procedures using MAGiC Sweep™, the first and only robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New Jersey. “We’re excited to be the first to demonstrate the value of robotic high-density mapping and to offer this important innovation to our patients,” said Dr. Corbisiero, Chief of Electrophysiology at Deborah Heart and Lung Center. “The ability to create a more accurate, detailed map of complex anatomy is important in diagnosing and treating arrhythmias. We have been impressed with the catheter during our experience mapping several different arrhythmias in the atria and ventricles.” “Navigating MAGiC Sweep to any desired cardiac location was easy, the catheter maintained stable contact with cardiac tissue, electrogram signals were very clear, and the catheter caused no ectopy in the ventricle,” added Dr. Kazemian, Program Director of EP Fellowship at Deborah Heart and Lung Center. “This is a significant leap forward for the community of robotic electrophysiologists and we look forward to the positive impact its expanded use will have on our patients and the EP field.” Stereotaxis has initiated commercial launch of MAGiC Sweep in the United States following recent FDA clearance of the catheter. MAGiC Sweep has been submitted for regulatory clearance in Europe. About StereotaxisStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled. Stereotaxis Contacts: David L. FischelChairman and Chief Executive Officer Kimberly PeeryChief Financial Officer 314-678-6100Investors@Stereotaxis.com

Related News